Trial Profile
A Dose Selection Phase 1 Study Evaluating the Safety and Tolerability of Silmitasertib
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs Silmitasertib (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Senhwa Biosciences
- 21 Dec 2023 Status changed from active, no longer recruiting to completed.
- 20 Apr 2023 New trial record